Cargando…

Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases

CONTEXT: Resistance to BCR-ABL tyrosine kinase inhibitor (TKI) is the cause of treatment failure in blast phase chronic myeloid leukaemia (BP-CML). Agents that act synergistically with BCR-ABL TKI are required to improve response. OBJECTIVE: This work investigated the effects of stachydrine in CML....

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Ruixin, Zhang, Wei, Xu, Dandan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967197/ https://www.ncbi.nlm.nih.gov/pubmed/35348419 http://dx.doi.org/10.1080/13880209.2022.2044862

Ejemplares similares

Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia()
por: Lam Yi, Hui, et al.
Publicado: (2019)

Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
por: Baccarani, Michele, et al.
Publicado: (2022)

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
por: Copland, Mhairi
Publicado: (2022)

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors
por: Nishiyama-Fujita, Yuriko, et al.
Publicado: (2022)

Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors
por: Rychter, Anna, et al.
Publicado: (2017)

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
por: Lindström, H. Jonathan G., et al.
Publicado: (2019)

Effect of stachydrine hydrochloride to the prostate hyperplasia model in mice
por: Tian, Shuo, et al.
Publicado: (2019)

South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook
por: Hodkinson, Katherine E., et al.
Publicado: (2022)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
por: Clark, Richard E.
Publicado: (2019)

Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
por: Allegra, Sarah, et al.
Publicado: (2023)

Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
por: Avenoso, Daniele, et al.
Publicado: (2021)

Molecular evidence for the clonal origin of blast crisis in chronic myeloid leukaemia.
por: Zalcberg, J. R., et al.
Publicado: (1986)

Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.
por: Gangal, S. G., et al.
Publicado: (1979)

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
por: Chen, Z, et al.
Publicado: (2016)

Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia
por: Jiang, Liling, et al.
Publicado: (2022)

Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
por: Zhou, H, et al.
Publicado: (2017)

The influence of stachydrine hydrochloride on the reperfusion model of mice with repetitive cerebral ischemia
por: Miao, Mingsan, et al.
Publicado: (2017)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
por: Shi, Ping, et al.
Publicado: (2010)

Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration
por: Xiang, Wei, et al.
Publicado: (2015)

The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia
por: Crisan, AM, et al.
Publicado: (2015)

Combination of curaxin and tyrosine kinase inhibitors display enhanced killing of primitive Chronic Myeloid Leukaemia cells
por: Pearson, Stella, et al.
Publicado: (2022)

Promyelocytic Blast Crisis of Chronic Myeloid Leukemia in a Patient Undergoing Therapy with a Tyrosine Kinase Inhibitor
por: Parsi, Meghana, et al.
Publicado: (2020)

Cytotoxic effects of tumour necrosis factor and gamma-interferon on acute myeloid leukaemia blasts.
por: Price, G., et al.
Publicado: (1987)

Cup‐like blasts in acute myeloid leukaemia with NPM1 and IDH2 mutations
por: Ohya, Eiko, et al.
Publicado: (2021)

Stachydrine protects eNOS uncoupling and ameliorates endothelial dysfunction induced by homocysteine
por: Xie, Xinya, et al.
Publicado: (2018)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
por: Kong, Jee Hyun, et al.
Publicado: (2020)

The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib
por: G. Lindström, H. Jonathan, et al.
Publicado: (2020)

Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies
por: Hewison, Ann, et al.
Publicado: (2020)

Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022)

COVID-19 in patients with chronic myeloid leukaemia on tyrosine kinase inhibitor therapy: a Honduran observational study
por: Fajardoa, Carlos J, et al.
Publicado: (2022)

Stachydrine ameliorates hypoxia reoxygenation injury of cardiomyocyte via enhancing SIRT1-Nrf2 pathway
por: Zhu, Xi, et al.
Publicado: (2023)

Stachydrine prevents LPS‐induced bone loss by inhibiting osteoclastogenesis via NF‐κB and Akt signalling
por: Meng, Jiahong, et al.
Publicado: (2019)

Current Management of Chronic Myeloid Leukemia Myeloid Blast Phase
por: Yohanan, Binoy, et al.
Publicado: (2022)

A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7)
por: Karkuzhali, Ponnuswamy, et al.
Publicado: (2013)

Molecular docking analysis of stachydrine and sakuranetin with IL-6 and TNF-α in the context of inflammation
por: Prathap, Lavanya, et al.
Publicado: (2021)

Stachydrine, a Bioactive Equilibrist for Synephrine, Identified from Four Citrus Chinese Herbs
por: Sun, Yifei, et al.
Publicado: (2023)

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
por: Romo-González, Marta, et al.
Publicado: (2020)

Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol
por: Balakumaran, Janatani, et al.
Publicado: (2019)

Stachydrine Ameliorates Cardiac Fibrosis Through Inhibition of Angiotensin II/Transformation Growth Factor β1 Fibrogenic Axis
por: Liu, Xiao, et al.
Publicado: (2019)

SRC-Family Kinases in Acute Myeloid Leukaemia and Mastocytosis
por: Voisset, Edwige, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hlcgrrmdmnhbd7pvg75kn0rvm3